DIVISLAB
PharmaceuticalsDivi's Laboratories Ltd.
Divis Laboratories was established in 1990; it manufactures the Active Pharma Ingredients (APIs) and intermediates. It focuses on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company has expanded its breadth of working operations in a short period with the purpose to provide complete turnkey solutions to the Indian Pharmaceutical Industry.
And with the five years of experience, and expertise, and a proven track–a record of helping many companies with its turnkey and consulting strengths, it had also established its first manufacturing facility in 1995. Its manufacturing plant is built on a 300-acre site at Hyderabad and its second manufacturing plant is located in Vishakhapatnam on a 314-acre site. It also has a presence in both New Jersey as well as Switzerland.
Currently, both the facilities are engaged in the manufacture of given components:
Active Pharmaceutical Ingredients (APIs) & Intermediates for Generics
The Custom Synthesis of API's and Advanced intermediates for discovery compounds for pharma giants
The Company in Hyderabad has also been successfully inspected by the US FDA during September 2000, in April 2004 and even in February 2008. Whereas it's Unit–2 is situated at Visakhapatnam and was also successfully inspected by the US FDA during November 2006 and in April 2009. It also undertakes various FTE/Contract Research on process development for the discovery of new compounds for the leading M.N.C.s across the globe and their consecutive partners for the supply of APIs. The company is global in its outlook & it benchmarks the quality standards, which are the best in the world.
- Trades at a P/E of 75, with a return on equity (ROE) of 12.2%.
- DIVISLAB is trading above 4 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bullish technical setup.
- Year-to-date it is up 15.95%, and up 12.8% over the past year.
- At ₹7,248.50 it sits about 89% of the way up its 52-week range (₹5,636.50–₹7,438.50).
- Offers a dividend yield of 0.66%.
- Market capitalisation stands at ₹1.92L Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Mar 2023 | ₹7,625 Cr | ₹1,808 Cr | ₹68.11 | 23.71% |
| Mar 2022 | ₹8,960 Cr | ₹2,960 Cr | ₹111.52 | 33.04% |
| Mar 2021 | ₹6,969 Cr | ₹1,984 Cr | ₹74.75 | 28.47% |
| Mar 2021 | ₹6,969 Cr | ₹1,984 Cr | ₹74.75 | 28.47% |
| Mar 2020 | ₹5,394 Cr | ₹1,377 Cr | ₹51.85 | 25.53% |
| Mar 2020 | ₹5,394 Cr | ₹1,377 Cr | ₹51.85 | 25.53% |
| Mar 2019 | ₹4,946 Cr | ₹1,353 Cr | ₹50.96 | 27.36% |
| Mar 2019 | ₹4,946 Cr | ₹1,353 Cr | ₹50.96 | 27.36% |
| Mar 2018 | ₹3,891 Cr | ₹877 Cr | ₹33.04 | 22.54% |
| Mar 2017 | ₹4,064 Cr | ₹1,060 Cr | ₹39.95 | 26.08% |
| Mar 2016 | ₹3,776 Cr | ₹1,126 Cr | ₹42.41 | 29.82% |
| Mar 2015 | ₹3,115 Cr | ₹852 Cr | ₹60.08 | 27.35% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| SUNPHARMA SUN PHARMACEUTICAL INDUSTRIES LTD. | 39.1 | ₹98.33 | 10.1% |
| MARKSANS MARKSANS PHARMA LTD. | 23.8 | ₹11.85 | 5.8% |
| MOREPENLAB MOREPEN LABORATORIES LTD. | 20.81 | ₹6.43 | 16.6% |
| NEULANDLAB NEULAND LABORATORIES LTD. | 23.48 | ₹542.16 | 9.35% |
| GUFICBIO Gufic BioSciences Ltd. | 24.16 | ₹10.85 | 20.41% |
| DRREDDY DR.REDDY'S LABORATORIES LTD. | 19.73 | ₹852.69 | 1.07% |
| RPGLIFE RPG LIFE SCIENCES LTD. | 17.14 | ₹105.02 | 5.73% |
| GLAND Gland Pharma Ltd | 53.6 | ₹242.00 | — |
| ZYDUSLIFE Zydus Lifesciences Ltd | 8.23 | ₹166.00 | 5% |
| SMSPHARMA SMS PHARMACEUTICALS LTD. | 9.58 | ₹42.07 | -8.73% |
| CIPLA CIPLA LTD. | 15.36 | ₹209.71 | 0.7% |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 25 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 1,12,509 | ₹3,612.00 |
| 25 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 1,12,509 | ₹3,612.00 |
| 17 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 1,76,805 | ₹3,572.80 |
| 17 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 1,76,805 | ₹3,572.80 |
| 11 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 1,72,889 | ₹3,686.60 |
| 11 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 1,72,889 | ₹3,686.60 |
| 19 Sept 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 1,17,596 | ₹3,573.70 |
| 19 Sept 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 1,17,596 | ₹3,573.70 |
| 01 Aug 2022 | ISHARES INDIA INDEX MAURITIUS COMPANY | SALE | 1,56,778 | ₹3,831.65 |
| 01 Aug 2022 | ISHARES MSCI INDIA ETF | PURCHASE | 1,56,778 | ₹3,831.65 |
| 18 Jul 2022 | ISHARES INDIA 50 ETF | PURCHASE | 20,608 | ₹3,727.75 |
| 18 Jul 2022 | ISHARES INDIA INDEX MAURITIUS COMPANY | SALE | 1,57,719 | ₹3,727.75 |
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.